Aurinia – $173 Million Offering

San Francisco – March 23, 2017 – Cooley advised Aurinia Pharmaceuticals on its $173 million public offering of 25,645,000 common shares, which includes the full exercise of the underwriters’ option to purchase 3,345,000 additional shares.

Aurinia, which is based in Victoria, British Columbia, and trades on The NASDAQ Global Market as “AUPH,” is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high un-met medical need. It is currently developing an investigational drug, voclosporin, for the treatment of lupus nephritis.

In January, Cooley advised Aurinia on its $28.75 million public offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.